Deciphering the Patent-Eligibility Message in Prometheus, Myriad and Classen
Article co-written by Yuri Levin-Schwartz, Ph.D., a law clerk at MBHB.
- Winter 2012 (snippets)
- Snippets
About The author
Kevin E. Noonan
Kevin E. Noonan is co-Chair of MBHB’s Biotechnology and Pharmaceuticals Practice Group. Dr. Noonan is an experienced patent lawyer, molecular biologist and renowned thought leader in biotechnology and pharmaceutical patent law. Over the past 30 years, he has counseled some of the largest biotechnology and pharmaceutical companies in the world on intellectual property issues.
© 2023 McDonnell Boehnen Hulbert & Berghoff LLP
snippets is a trademark of McDonnell Boehnen Hulbert & Berghoff LLP. All rights reserved. The information contained in this newsletter reflects the understanding and opinions of the author(s) and is provided to you for informational purposes only. It is not intended to and does not represent legal advice. MBHB LLP does not intend to create an attorney–client relationship by providing this information to you. The information in this publication is not a substitute for obtaining legal advice from an attorney licensed in your particular state. snippets may be considered attorney advertising in some states.